Rybrevant (amivantamab-vmjw)
Janssen Oncology (Johnson & Johnson) · Bispecific Antibody — EGFR × MET
What is Rybrevant? Rybrevant (amivantamab-vmjw) is a bispecific antibody targeting EGFR and MET by Janssen. It is FDA-approved for NSCLC with EGFR exon 20 insertion mutations, and in combination with lazertinib for EGFR-mutant NSCLC after osimertinib and platinum chemotherapy.
About Rybrevant
| Brand Name | Rybrevant |
| Generic / INN | amivantamab-vmjw |
| Drug Class | Bispecific Antibody — EGFR × MET |
| Manufacturer | Janssen Oncology (Johnson & Johnson) |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 2021 |
FDA-Approved Uses for Rybrevant
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations — after platinum-based chemotherapy
- Locally advanced or metastatic EGFR-mutated NSCLC — in combination with lazertinib (Lazcluze) after failure of osimertinib and platinum-based chemotherapy
- Locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations — first-line, in combination with lazertinib
How Does Rybrevant Work?
Amivantamab-vmjw simultaneously targets EGFR and MET receptors on tumor cells. It blocks ligand binding, promotes EGFR and MET receptor degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis — directly killing tumor cells through immune effector mechanisms in addition to receptor blockade.
Dosage & Administration
Weight-based dosing: 1050 mg IV (body weight <80 kg) or 1400 mg IV (body weight ≥80 kg). First infusion over 5 hours; subsequent infusions over 3 hours if previous infusion well tolerated. Premedication required to reduce infusion-related reactions.
Warnings, Precautions & Side Effects
General Warning
Infusion-related reactions — premedication required; split first dose over 2 days for high-risk patients. Interstitial lung disease / pneumonitis. Dermatologic toxicity (rash, paronychia) — very common. Ocular toxicity. Venous and arterial thromboembolism. Embryo-fetal toxicity.
Common Side Effects
- Rash (acneiform / dermatitis)
- Infusion-related reactions
- Paronychia
- Fatigue
- Nausea
- Edema
- Peripheral neuropathy
- Decreased appetite
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Rybrevant is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Rybrevant. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Rybrevant
Rybrevant (amivantamab-vmjw) is a bispecific EGFR×MET antibody by Janssen approved for NSCLC with EGFR exon 20 insertion mutations and in combination with lazertinib for other EGFR-mutant NSCLC settings.
EGFR exon 20 insertions are a specific type of EGFR mutation in non-small cell lung cancer that is generally resistant to first and second-generation EGFR inhibitors (gefitinib, erlotinib, afatinib) and even osimertinib. Rybrevant was the first FDA-approved therapy specifically for this mutation.
Dermatologic toxicity (acneiform rash, paronychia — nail inflammation) is very common with amivantamab. Proactive skin management with topical antibiotics and moisturizers is recommended.
Rybrevant is covered by Medicare Part B and commercial insurance for approved EGFR-mutant NSCLC indications with biomarker documentation and prior authorization. BiologicHealthPlus manages the full PA process.
Related Medications & Conditions
Related Medications
Lazcluze (lazertinib) · Tagrisso (osimertinib) · Keytruda (pembrolizumab) · Bizengri (zenocutuzumab)
Related Conditions
EGFR exon 20 insertion NSCLC · EGFR-mutant NSCLC · Non-small cell lung cancer